Skip to main content
SpringerLink
Log in

Lokale Radiotherapie für Patienten mit einem neu diagnostizierten, metastasierten Prostatakarzinom

Local radiotherapy for patients with newly diagnosed, metastatic prostate cancer

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Méjean A et al (2018) Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 379:417–427

    Article  PubMed  Google Scholar 

  2. Kaplan RN et al (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820–827

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Gundem G et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520:353–357

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Culp SH, Schellhammer PF, Williams MB (2014) Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 65:1058–1066

    Article  PubMed  Google Scholar 

  5. Löppenberg B et al (2017) The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: A national cancer data base analysis. Eur Urol 72:14–19

    Article  PubMed  Google Scholar 

  6. Rusthoven CG et al (2016) Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol 34:2835–2842

    Article  CAS  PubMed  Google Scholar 

  7. Leyh-Bannurah S‑R et al (2017) Local therapy improves survival in metastatic prostate cancer. Eur Urol 72:118–124

    Article  PubMed  Google Scholar 

  8. Parker CC et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): A randomised controlled phase 3 trial. Lancet 392:2353–2366

    Article  PubMed  PubMed Central  Google Scholar 

  9. Boevé LMS et al (2018) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary Bone metastatic prostate cancer in a prospective Randomised clinical trial: Data from the HORRAD trial. Eur Urol. https://doi.org/10.1016/j.eururo.2018.09.008

    Article  PubMed  Google Scholar 

  10. Antonia SJ et al (2018) Overall survival with Durvalumab after Chemoradiotherapy in stage III NSCLC. N Engl J Med 379:2342–2350

    Article  CAS  PubMed  Google Scholar 

  11. Pompe RS et al (2018) Survival benefit of local versus no local treatment for metastatic prostate cancer—Impact of baseline PSA and metastatic substages. Prostate 78:753–757

    Article  CAS  PubMed  Google Scholar 

  12. Wong HS et al (2018) Comparative study between 68 Ga-prostate-specific membrane antigen positron emission tomography and conventional imaging in the initial staging of prostate cancer. J Med Imaging Radiat Oncol 62:816–822

    Article  PubMed  Google Scholar 

  13. Dyrberg E et al (2018) 68 Ga-PSMA-PET/CT in comparison with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study. Eur Radiol. https://doi.org/10.1007/s00330-018-5682-x

    Article  PubMed  Google Scholar 

  14. Gravis G et al (2018) Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early Docetaxel: Further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol 73:847–855

    Article  PubMed  PubMed Central  Google Scholar 

  15. James ND et al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377:338–351

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ost P et al (2017) Surveillance or metastasis-directed therapy for Oligometastatic prostate cancer recurrence: A prospective, randomized, Multicenter phase II trial. J Clin Oncol 36:446–453

    Article  PubMed  Google Scholar 

  17. Donovan JL et al (2016) Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 375:1425–1437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Competence Center Palliative Care, University Hospital Zurich (USZ), Rämistrasse 100, 8091, Zurich, Schweiz

    Matthias Guckenberger

Authors
  1. Matthias Guckenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthias Guckenberger.

Ethics declarations

Interessenkonflikt

M. Guckenberger gibt an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation

Parker CC, James ND, Brawley CD, Clarke NW (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. The Lancet 392:2353–2366

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guckenberger, M. Lokale Radiotherapie für Patienten mit einem neu diagnostizierten, metastasierten Prostatakarzinom. Strahlenther Onkol 195, 362–364 (2019). https://doi.org/10.1007/s00066-019-01435-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-019-01435-8

Search

Navigation